LYRM9

Across TCGA pan-cancer cohorts, LYRM9 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LYRM9 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LYRM9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LYRM9 expression acts as an unfavorable survival marker.

HNSC and CHOL are the cancer types where LYRM9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.156	0.751	<.001	48	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

LYRM9–HNSC (OS)

Open the HNSC breakdown →